News O O O O
- O O O O
[Clone O O O O
of O O O O
Daily O O O O
statin O O O O
reduces O O O O
the O O O O
risk O O O O
of O O O O
cardiovascular O O O O
disease O O O O
in O O O O
people O O O O
living O O O O
with O O O O
HIV](/news/clone-of-daily-statin-reduces-the-risk-of-cardiovascular-disease-in-people-living-with-hiv) O O O O
Date: O O O O
04/12/2023 O O O O
Publication: O O O O
NIH O O O O
A O O O O
National O O O O
Institutes O O O O
of O O O O
Health O O O O
(NIH) O O O O
clinical O O O O
trial O O O O
was O O O O
stopped O O O O
early O O O O
because O O O O
a O O O O
daily O O O O
statin O O O O
medication O O O O
was O O O O
found O O O O
to O O O O
reduce O O O O
the O O O O
increased O O O O
risk O O O O
of O O O O
cardiovascular O O O O
disease O O O O
among O O O O
people O O O O
living O O O O
with O O O O
HIV O O O O
in O O O O
the O O O O
first O O O O
large-scale O O O O
clinical O O O O
study O O O O
to O O O O
test O O O O
a O O O O
primary O O O O
cardiovascular O O O O
prevention O O O O
strategy O O O O
in O O O O
this O O O O
population. O O O O
A O O O O
planned O O O O
interim O O O O
analysis O O O O
of O O O O
data O O O O
from O O O O
the O O O O
Randomized O O O O
Trial O O O O
to O O O O
Prevent O O O O
Vascular O O O O
Events O O O O
in O O O O
HIV O O O O
(REPRIEVE(link O O O O
is O O O O
external)) O O O O
study O O O O
found O O O O
that O O O O
participants O O O O
who O O O O
took O O O O
pitavastatin O O O O
calcium, O O O O
a O O O O
daily O O O O
statin, O O O O
lowered O O O O
their O O O O
risk O O O O
of O O O O
major O O O O
adverse O O O O
cardiovascular O O O O
events O O O O
by O O O O
35% O O O O
compared O O O O
with O O O O
those O O O O
receiving O O O O
a O O O O
placebo. O O O O
Adverse O O O O
drug O O O O
events O O O O
observed O O O O
in O O O O
the O O O O
study O O O O
were O O O O
like O O O O
those O O O O
in O O O O
the O O O O
general O O O O
population O O O O
taking O O O O
statin O O O O
therapy. O O O O
The O O O O
interim O O O O
analysis O O O O
was O O O O
sufficiently O O O O
compelling O O O O
that O O O O
the O O O O
study's O O O O
independent O O O O
Data O O O O
Safety O O O O
and O O O O
Monitoring O O O O
Board O O O O
(DSMB) O O O O
recommended O O O O
it O O O O
be O O O O
stopped O O O O
early O O O O
given O O O O
adequate O O O O
evidence O O O O
of O O O O
efficacy. O O O O
The O O O O
NIH O O O O
accepted O O O O
the O O O O
DSMB O O O O
recommendations. O O O O
REPRIEVE O O O O
began O O O O
in O O O O
2015 O O O O
and O O O O
enrolled O O O O
7,769 O O O O
volunteers O O O O
who O O O O
were O O O O
40 O O O O
to O O O O
75 O O O O
years O O O O
of O O O O
age, O O O O
of O O O O
whom O O O O
more O O O O
than O O O O
30% O O O O
were O O O O
women. O O O O
REPRIEVE O O O O
volunteers O O O O
were O O O O
all O O O O
taking O O O O
antiretroviral O O O O
therapy, O O O O
with O O O O
CD4+ O O O O
cell O O O O
counts O O O O
greater O O O O
than O O O O
100 O O O O
cells/mm3 O O O O
of O O O O
blood O O O O
at O O O O
enrollment, O O O O
and O O O O
had O O O O
low-to-moderate O O O O
traditional O O O O
cardiovascular O O O O
disease O O O O
risk O O O O
that O O O O
would O O O O
not O O O O
typically O O O O
be O O O O
considered O O O O
for O O O O
statin O O O O
treatment. O O O O
The O O O O
trial O O O O
was O O O O
conducted O O O O
in O O O O
12 O O O O
countries O O O O
in O O O O
Asia, O O O O
Europe, O O O O
North O O O O
America, O O O O
South O O O O
America O O O O
and O O O O
Africa. O O O O
Both O O O O
the O O O O
Baltimore O O O O
and O O O O
Pune, O O O O
India, O O O O
sites O O O O
from O O O O
the O O O O
Johns O O O O
Hopkins O O O O
Baltimore-India O O O O
Clinical O O O O
Trials O O O O
Unit O O O O
participated O O O O
in O O O O
this O O O O
important O O O O
effort O O O O
to O O O O
reduce O O O O
heart O O O O
disease O O O O
among O O O O
people O O O O
with O O O O
HIV. O O O O
CLICK O O O O
HERE O O O O
for O O O O
full O O O O
press O O O O
release. O O O O
A Reason 5 O O
National Reason 5 O O
Institutes Reason 5 O O
of Reason 5 O O
Health Reason 5 O O
(NIH) Reason 5 O O
clinical Reason 5 O O
trial Reason 5 O O
was Reason 5 O O
stopped Reason 5 O O
early Reason 5 O O
because Reason 5 O O
a Reason 5 O O
daily Reason 5 O O
statin Reason 5 O O
medication Reason 5 O O
was Reason 5 O O
found Reason 5 O O
to Reason 5 O O
reduce Reason 5 O O
the Reason 5 O O
increased Reason 5 O O
risk Reason 5 O O
of Reason 5 O O
cardiovascular Reason 5 O O
disease Reason 5 O O
among Reason 5 O O
people Reason 5 O O
living Reason 5 O O
with Reason 5 O O
HIV Reason 5 O O
in Reason 5 O O
the Reason 5 O O
first Reason 5 O O
large-scale Reason 5 O O
clinical Reason 5 O O
study Reason 5 O O
to Reason 5 O O
test Reason 5 O O
a Reason 5 O O
primary Reason 5 O O
cardiovascular Reason 5 O O
prevention Reason 5 O O
strategy Reason 5 O O
in Reason 5 O O
this Reason 5 O O
population. Reason 5 O O
A Reason 5 O O
planned Reason 5 O O
interim Reason 5 O O
analysis Reason 5 O O
of Reason 5 O O
data Reason 5 O O
from Reason 5 O O
the Reason 5 O O
Randomized Reason 5 O O
Trial Reason 5 O O
to Reason 5 O O
Prevent Reason 5 O O
Vascular Reason 5 O O
Events Reason 5 O O
in Reason 5 O O
HIV Reason 5 O O
(REPRIEVE(link Reason 5 O O
is Reason 5 O O
external)) Reason 5 O O
study Reason 5 O O
found Reason 5 O O
that Reason 5 O O
participants Reason 5 O O
who Reason 5 O O
took Reason 5 O O
pitavastatin Reason 5 O O
calcium, Reason 5 O O
a Reason 5 O O
daily Reason 5 O O
statin, Reason 5 O O
lowered Reason 5 O O
their Reason 5 O O
risk Reason 5 O O
of Reason 5 O O
major Reason 5 O O
adverse Reason 5 O O
cardiovascular Reason 5 O O
events Reason 5 O O
by Reason 5 O O
35% Reason 5 O O
compared Reason 5 O O
with Reason 5 O O
those Reason 5 O O
receiving Reason 5 O O
a Reason 5 O O
placebo. Reason 5 O O
Adverse Reason 3 O O
drug Reason 3 O O
events Reason 3 O O
observed Reason 3 O O
in Reason 3 O O
the Reason 3 O O
study Reason 3 O O
were Reason 3 O O
like Reason 3 O O
those Reason 3 O O
in Reason 3 O O
the Reason 3 O O
general Reason 3 O O
population Reason 3 O O
taking Reason 3 O O
statin Reason 3 O O
therapy. Reason 3 O O
The Reason 5 O O
interim Reason 5 O O
analysis Reason 5 O O
was Reason 5 O O
sufficiently Reason 5 O O
compelling Reason 5 O O
that Reason 5 O O
the Reason 5 O O
study's Reason 5 O O
independent Reason 5 O O
Data Reason 5 O O
Safety Reason 5 O O
and Reason 5 O O
Monitoring Reason 5 O O
Board Reason 5 O O
(DSMB) Reason 5 O O
recommended Reason 5 O O
it Reason 5 O O
be Reason 5 O O
stopped Reason 5 O O
early Reason 5 O O
given Reason 5 O O
adequate Reason 5 O O
evidence Reason 5 O O
of Reason 5 O O
efficacy. Reason 5 O O
The Reason 5 O O
NIH Reason 5 O O
accepted Reason 5 O O
the Reason 5 O O
DSMB Reason 5 O O
recommendations. Reason 5 O O
REPRIEVE Reason 4 O O
began Reason 4 O O
in Reason 4 O O
2015 Reason 4 O O
and Reason 4 O O
enrolled Reason 4 O O
7,769 Reason 4 O O
volunteers Reason 4 O O
who Reason 4 O O
were Reason 4 O O
40 Reason 4 O O
to Reason 4 O O
75 Reason 4 O O
years Reason 4 O O
of Reason 4 O O
age, Reason 4 O O
of Reason 4 O O
whom Reason 4 O O
more Reason 4 O O
than Reason 4 O O
30% Reason 4 O O
were Reason 4 O O
women. Reason 4 O O
REPRIEVE Reason 4 O O
volunteers Reason 4 O O
were Reason 4 O O
all Reason 4 O O
taking Reason 4 O O
antiretroviral Reason 4 O O
therapy, Reason 4 O O
with Reason 4 O O
CD4+ Reason 4 O O
cell Reason 4 O O
counts Reason 4 O O
greater Reason 4 O O
than Reason 4 O O
100 Reason 4 O O
cells/mm3 Reason 4 O O
of Reason 4 O O
blood Reason 4 O O
at Reason 4 O O
enrollment, Reason 4 O O
and Reason 4 O O
had Reason 4 O O
low-to-moderate Reason 4 O O
traditional Reason 4 O O
cardiovascular Reason 4 O O
disease Reason 4 O O
risk Reason 4 O O
that Reason 4 O O
would Reason 4 O O
not Reason 4 O O
typically Reason 4 O O
be Reason 4 O O
considered Reason 4 O O
for Reason 4 O O
statin Reason 4 O O
treatment. Reason 4 O O
The Reason 3 O O
trial Reason 3 O O
was Reason 3 O O
conducted Reason 3 O O
in Reason 3 O O
12 Reason 3 O O
countries Reason 3 O O
in Reason 3 O O
Asia, Reason 3 O O
Europe, Reason 3 O O
North Reason 3 O O
America, Reason 3 O O
South Reason 3 O O
America Reason 3 O O
and Reason 3 O O
Africa. Reason 3 O O
Both Reason 4 O O
the Reason 4 O O
Baltimore Reason 4 O O
and Reason 4 O O
Pune, Reason 4 O O
India, Reason 4 O O
sites Reason 4 O O
from Reason 4 O O
the Reason 4 O O
Johns Reason 4 O O
Hopkins Reason 4 O O
Baltimore-India Reason 4 O O
Clinical Reason 4 O O
Trials Reason 4 O O
Unit Reason 4 O O
participated Reason 4 O O
in Reason 4 O O
this Reason 4 O O
important Reason 4 O O
effort Reason 4 O O
to Reason 4 O O
reduce Reason 4 O O
heart Reason 4 O O
disease Reason 4 O O
among Reason 4 O O
people Reason 4 O O
with Reason 4 O O
HIV. Reason 4 O O
CLICK Reason 3 O O
HERE Reason 3 O O
for Reason 3 O O
full Reason 3 O O
press Reason 3 O O
release. Reason 3 O O
- O O O O
1 O O O O
[2](http://bwictu.jhu.edu/news/P10) O O O O
[3](http://bwictu.jhu.edu/news/P20) O O O O
[>](http://bwictu.jhu.edu/news/P10) O O O O
[Last O O O O
](http://bwictu.jhu.edu/news/P40) O O O O
- O O O O
